SUPERNEWS - NASDAQ:MRNA (Moderna, Inc.) Stock Price, News, Quote, History

SUPERNEWS

Equities

Top Stories

Moderna vs. Pfizer in London Over mRNA Patents

4/22, 00:11 EDT

Moderna Halts $500M Kenya Plant Amid $1B Loss, Low Demand

Moderna halts $500 million mRNA plant in Kenya amid no new vaccine orders and over $1 billion in losses.

4/11, 07:49 EDT

Moderna's mRNA-1283 Vaccine Shows Promising Results in Phase-3 Trial

Moderna's nextgen COVID-19 vaccine shows stronger immune response, boosting stock by 13% and expanding beyond COVID with a promising pipeline.

3/26, 09:12 EDT

AstraZeneca Halts Vaxzevria Amid Falling Demand, Not Safety

AstraZeneca ends Vaxzevria's run due to falling demand, not safety concerns, amidst evolving vaccine preferences and legal challenges.

5/8, 05:34 EDT

Moderna Shifts Focus to Diversification Amid Revenue Decline

Moderna aims to cut R&D spending by 7% to $4.5 billion amid a 64% revenue drop, focusing on diversification and efficiency.

3/6, 07:09 EST

Moderna vs. Pfizer in London Over mRNA Patents

4/22, 00:11 EDT

Moderna Halts $500M Kenya Plant Amid $1B Loss, Low Demand

4/11, 07:49 EDT

Moderna's mRNA-1283 Vaccine Shows Promising Results in Phase-3 Trial

3/26, 09:12 EDT

MRNA News

AlphaFold 3 by Google DeepMind Revolutionizes Disease Understanding and Drug Discovery

5/8, 11:29 EDT

AstraZeneca Halts Vaxzevria Amid Falling Demand, Not Safety

5/8, 05:34 EDT

Boston Properties and Brammer Bio Clash Over Kendall Construction

5/2, 14:34 EDT

S&P 500, Nasdaq Up Post-Powell; Qualcomm Leads Chip Surge

5/2, 13:48 EDT

Citi's Top Biotech Picks in $2.9B Market, Ionis Gets 50% Upside

4/30, 19:34 EDT

HeartSciences Eyes Lead in Growing $25B AI ECG Market

4/30, 09:53 EDT

AI in Healthcare to Hit $187.95B by 2030, Moderna & Cardio Lead Charge

4/30, 08:18 EDT

Novo, Stellantis Eye Gains in EMEA Amid Market Tests

4/26, 05:22 EDT

AI Healthcare Boom: BNAI Aims High with $148B Forecast by 2029

4/25, 08:29 EDT

AI and Telehealth Revolutionizing Healthcare for Cardiovascular Disease

4/23, 09:29 EDT

Moderna vs. Pfizer in London Over mRNA Patents

4/22, 00:11 EDT

Sands' Sales Up 40%, Beats Estimates Amid Macau Rebound

4/17, 17:29 EDT

Shah Capital Pushes Novavax for Board Revamp, New Sales Plan

4/15, 00:15 EDT

Vertex Buys Alpine for $4.9B, Aims Beyond Cystic Fibrosis

4/11, 11:13 EDT

Moderna Halts $500M Kenya Plant Amid $1B Loss, Low Demand

4/11, 07:49 EDT

Stocks Dip, Gold Peaks at $2,343; Bitcoin Below $70K Before CPI Data

4/9, 14:12 EDT

Intraday: Market Wavers: Inflation Fears, Acrivon's 91% Surge

4/9, 14:07 EDT

Intraday: Moderna and BlackBerry Soar, Tilray Tumbles Amid Market Jitters

4/9, 10:36 EDT

Unveiling the AI Tech Stack: Navigating the Revolution with Caution

4/5, 09:04 EDT

Intraday: Biotech Surges, Tech Tumbles: Market's Mixed Signals

4/3, 13:36 EDT

Moderna's Strategic Expansion Signals Shift Beyond COVID-19 Vaccines

3/27, 09:31 EDT

Moderna's mRNA-1283 Vaccine Shows Promising Results in Phase-3 Trial

3/26, 09:12 EDT

Pre-Market: Market Wavers: Tech Struggles, Healthcare Shines Amid Uncertainty

3/25, 08:33 EDT

Breakthrough Gene-Edited Pig Kidney Transplant Offers Hope for Organ Shortage

3/21, 12:20 EDT

BioNTech Earnings Miss Estimates, Revenue Drops 66% Amid Reduced Vaccine Demand

3/20, 08:09 EDT

Contrarian Investment Opportunities Identified by Goldman Sachs

3/13, 15:41 EDT

Third Point Sparks Advance Auto Parts Rally

3/11, 19:24 EDT

Intraday: Markets Wobble as Investors Eye Inflation, Fed Moves

3/11, 13:30 EDT

Intraday: Market Wobbles Amid Economic Fears, Select Stocks Soar

3/11, 10:25 EDT

Navigating Uncertainty in Pharma Investments: Moderna's CFO Shares Strategic Insights

3/11, 05:39 EDT

Wall Street Views

Healthcare Strategist at financial-services firm

Karen Andersen, 3/6/24

MRNA

“It’s a lot of juggling different kinds of trials and trying to figure out when the company has flexibility to make some decisions on adding some more trials.”

AJ Bell

Russ Mould, 2/22/24

Bullish on

MRNA

NEM

NVDA

“The big fear in recent days was that a disappointing quarter from Nvidia would lead to a loss of investor confidence in the tech space and that could cause contagion on the markets... Crisis has been averted after Nvidia smashed expectations with its latest results…a large beat on both earnings and sales has put a new rocket under the stock.”

Swissquote Bank

Ipek Ozkardeskaya, 2/22/24

Bullish on

MRNA

NEM

NVDA

“So, there you go, ladies and gentlemen, a potential misstep from Nvidia that would hammer the AI rally has simply not come. What now? The rally will probably continue.”

Evercore ISI

Julian Emanuel, 2/22/24

MRNA

NEM

NVDA

“FOMO remains bid.”